The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy

The aim of the study was the evaluation of structural-functional data of the left ventricle (LV) at doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy. Monitoring of 99 patients had been performed: 49 with onco-hematological diseases and 50 with idiopathic dilatative cardiomyopathy. According to the total dose of doxorubicin the patients had been divided to three sub-groups: I subgroup -- 232.2+/-5.8 mg/m(2), II subgroup - 388+/-15.3mg/m(2), III subgroup - 533.1+/-13.6 mg/m(2). It had been revealed the dose-depending evolution of cardiotoxic effect of doxorubicin leading to the development of anthracyclic cardiomyopathy. At anthracyclic cardiomyopathy LV undergoes the same structural-functional changes as the idiopathic dilatative cardiomyopathy. The cardiotoxic effect of doxorubicin is revealed already at law summary dose of 232 mg/m(2), at "critical dose" 356-388 mg/m(2) develops diastolic dysfunction of LV with clinical manifestation of heart failure, and by summary dose of 533 mg/m(2) develops anthracyclic dilatative cardiomyopathy with systolic-diastolic dysfunction of LV and with clinical manifestation of the heart failure.